From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy.

摘要: Background. Inhibition of the epidermal growth factor receptor pathway with tyro sine kinase inhibitors can improve outcome patients advanced non-small cell lung cancer after first-line chemotherapy. The use clinical characteristics and mo lecular markers may permit identification who are more likely to ben efit from erlotinib. Patients methods. Retrospective analysis unselected metastatic had previously failed on at least one line chemotherapy treated our institution erlotinib (150 mg/day orally) until disease progression. Mutations (exon 19-21) KRAS (codon 12-13) genes were screened high-resolution melting identified direct sequencing. Results. Fifty-three included in study. control rate was 38%. Median progression-free survival median overall 4 15 months, respectively. Skin rash, diarrhea mucositis most common toxi cities In 19 patients, dose reduced for toxicity. significantly better non-smokers, responders mu tations. Overall longer skin toxicity mutations. Conclusions . experience, mutations, re sponse previous non-smoking status predictors higher survival. signif icantly mutations